Advancing Obesity Care: Stay Informed with the Boston Course in Obesity Medicine 2023
Join us in embracing the rapid evolution of obesity management and its associated complications through cutting-edge therapies, practice guidelines, and care models. The Boston Course in Obesity Medicine presents a professional education program meticulously updated for 2023, designed to empower clinicians, researchers, policymakers, and the obesity care community to navigate the dynamic landscape of obesity science and clinical practice.
Highlights from a Remarkable Year in Obesity Science and Clinical Practice
The past year has witnessed remarkable progress in the realm of obesity science and clinical care. This year’s program will delve into the following highlights:
The groundbreaking SURMOUNT-1 study, unveiling the results of the first phase 3 trial of tirzepatide treatment, showcasing an impressive average 22% weight loss.
Insights from the STEP TEENS study, revealing the efficacy of semaglutide 2.4 mg weekly in treating obesity among adolescents, with an average 17% weight loss.
FDA approval of semaglutide 2.4 mg weekly for treating obesity in adolescents, marking a significant milestone.
Fresh perspectives from the American Academy of Pediatrics clinical practice guidelines for obesity treatment in children and adolescents.
Significant outcomes from the SELECT study, assessing the impact of semaglutide 2.4 mg weekly on cardiovascular outcomes in obesity patients without diabetes.
An updated report from the Institute for Clinical and Economic Review, assessing the utility and cost-effectiveness of anti-obesity medications.
Novel insights into the mechanisms of the body’s resistance to weight loss through calorie reduction alone, with GLP-1 receptor agonists demonstrating the potential to overcome this resistance.
Revelation of the adverse effects of highly processed foods through new studies.
Exploration of the benefits and limitations of timed feeding and intermittent fasting, backed by new research.
Comprehensive understanding of the clinical and psychosocial impacts of weight-related bias, stigma, and discrimination.
Introduction of new Canadian clinical practice guidelines for obesity evaluation and management.
One-year phase 2 trial results of resmetirom, showcasing NASH resolution and liver fibrosis improvement.
Multiple clinical practice guidelines for the evaluation and management of NAFLD and NASH patients.
Landmark findings on long-term cancer outcomes post-bariatric surgery, highlighting significant improvements in cancer incidence and mortality rates.
Unveiling of data demonstrating the positive impact of metabolic and bariatric surgery on markers of kidney disease.
Identification of effective strategies to optimize the benefits and safety of metabolic and bariatric surgery.
Release of updated clinical practice guidelines for the selection and utilization of metabolic and bariatric surgery.
Compelling evidence of the benefits of endoscopic approaches in treating obesity, diabetes, and NAFLD.
Demonstrated advantages of combination and multimodal treatments for obesity.
Innovations in organizing and disseminating efficient obesity care models.
Collaborative efforts to enhance equitable patient access to effective obesity care.
Emergence of startups aiming to streamline access to impactful obesity care.
Growing recognition from payers and policymakers regarding the clinical and economic advantages of effective obesity treatment, with potential improvements in reimbursement.
Program Overview:
Obesity Medicine Board Review
Stay current with the core principles and advancements in the field of Obesity Medicine.
Obesity Treatment 2023
Dive deep into the latest therapies, research, guidelines, and care models driving obesity treatment forward.
Be a part of the ongoing transformation in obesity care. Join us for the Boston Course in Obesity Medicine 2023 to harness the knowledge, insights, and collaborative spirit that will shape the future of obesity management.
